The new approach in modern medicine is the concept of “liquid biopsy”, where the molecular markers are analyzed in bio-fluid samples. Liquid biopsy is a powerful tool for non-invasive cancer diagnosis, tumor profiling, evaluation of response to therapy, and follow-up after treatment. Extracellular vesicles (EVs) are promising for liquid biopsy tests because they are enriched in biomarkers that reflect the composition of the cell they originate from.
Most EV-based liquid biopsy tests analyse RNA and DNA markers, however, the gold standard of tumor profiling is the analysis of protein markers on tumor cells. The detection of commonly used histological markers on EVs could provide more complete information about the tumor phenotype and provide a shorter path to the clinic.
However, surface density of pathological proteins on EV membrane could be low, thus highly sensitive techniques are required to detect cancer biomarkers on extracellular vesicles. Exosome Analytics has developed technologies that address this challenge and offer sensitivities that are order of magnitude above that of existing products.
